Soligenix, Inc. (SNGX) stock
SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.01 (-2.67%)
Close on Nov 17, 2026Market cap $6.11MP/E –Yield –
Soligenix price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Soligenix's price to sales ratio was 41.5× on Apr 30, 2025, against 4.8× a year earlier. Over the last 5 years it ranged from 1.8× to 48.7×, with a median of 14.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 41.5× | +24.5 |
| 2024 | Dec 31, 2024 | 17.0× | +8.8 |
| 2023 | Dec 29, 2023 | 8.2× | −14.4 |
| 2022 | Dec 30, 2022 | 22.6× | −9.8 |
| 2021 | Dec 31, 2021 | 32.4× | +24.1 |
| 2020 | Dec 31, 2020 | 8.3× | +3.2 |
| 2019 | Dec 31, 2019 | 5.0× | +2.3 |
| 2018 | Dec 31, 2018 | 2.8× | +0.5 |
| 2017 | Dec 29, 2017 | 2.3× | +1.5 |
| 2016 | Dec 30, 2016 | 0.7× | −3.2 |
| 2015 | Dec 31, 2015 | 4.0× | +0.6 |
| 2014 | Dec 31, 2014 | 3.3× | −9.7 |
| 2013 | Dec 31, 2013 | 13.0× | +12.1 |
| 2012 | Dec 31, 2012 | 0.9× | −67.2 |
| 2011 | Dec 30, 2011 | 68.1× | – |
See a number that looks wrong?